Octreotide
1
Reactions 516 - 27 Aug 1994 ★ Octreotide First report of hyperkalaemia in an elderly patient: case report A 68-year-old woman, with noninsulin-dependent diabetes mellitus, developed hyperkalaemia approximately 24 hours after she received SC octreotide 100µg three times daily. The woman underwent surgery following a car accident and on day 16 octreotide therapy was started to decrease the output from a pancreatic fistula. On day 18 it was noted that the woman’s serum potassium level was increasing and her enteral feedings were altered in response to the increase. On day 19 her serum potassium level was 6.5 mmol/L (normal 3.5–5.0) and after she received polystyrene sulfate the level decreased to 5.9 mmol/L. However, on day 20 the patient’s serum potassium level was still elevated at 5.6 mmol/L. The next day octreotide therapy was stopped and her serum potassium level subsequently decreased to 4.3 mmol/L on day 22. The following day a challenge dose of SC octreotide 100µg was administered and the woman’s serum potassium level increased from 4.8 to 5.8 mmol/L and remained elevated for 3 days. The woman was asymptomatic during the episodes of hyperkalaemia. Author comment: ‘We believe that this is the first reported case of octreotide-induced hyperkalaemia.’ Sargent AI, et al. Octreotide-induced hyperkalemia. Pharmacotherapy 14: 497-501, Jul-Aug 1994 - USA 800288103 1 Reactions 27 Aug 1994 No. 516 0114-9954/10/0516-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Octreotide
Reactions 516 - 27 Aug 1994
★Octreotide
First report of hyperkalaemia in an elderly patient:case report
A 68-year-old woman, with noninsulin-dependent diabetesmellitus, developed hyperkalaemia approximately 24 hoursafter she received SC octreotide 100µg three times daily.
The woman underwent surgery following a car accident andon day 16 octreotide therapy was started to decrease theoutput from a pancreatic fistula.
On day 18 it was noted that the woman’s serum potassiumlevel was increasing and her enteral feedings were altered inresponse to the increase. On day 19 her serum potassium levelwas 6.5 mmol/L (normal 3.5–5.0) and after she receivedpolystyrene sulfate the level decreased to 5.9 mmol/L.However, on day 20 the patient’s serum potassium level wasstill elevated at 5.6 mmol/L. The next day octreotide therapywas stopped and her serum potassium level subsequentlydecreased to 4.3 mmol/L on day 22.
The following day a challenge dose of SC octreotide 100µgwas administered and the woman’s serum potassium levelincreased from 4.8 to 5.8 mmol/L and remained elevated for 3days. The woman was asymptomatic during the episodes ofhyperkalaemia.
Author comment: ‘We believe that this is the first reportedcase of octreotide-induced hyperkalaemia.’Sargent AI, et al. Octreotide-induced hyperkalemia. Pharmacotherapy 14: 497-501,Jul-Aug 1994 - USA 800288103
1
Reactions 27 Aug 1994 No. 5160114-9954/10/0516-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
